1	Plasma Neurofilament Light Chain predicts cognitive progression
2	in prodromal and clinical dementia with Lewy Bodies
3	
4	Andrea Pilotto, MD ^{a,b*\$} and Alberto Imarisio, MD ^{a\$} , Claudia Carrarini, MD ^c , Mirella Russo,
5	MD ^{c,} , Stefano Masciocchi, MD ^a , Stefano Gipponi, MD ^a , Elisabetta Cottini, MD ^a , Dag
6	Aarsland ^e , Henrik Zetterberg, MD, PhD ^{f,g,h,i} , Nicholas J. Ashton, MSc, PhD ^{f,j,k,l} , Abdul Hye,
7	PhD ^{k,l} , Laura Bonanni, MD, PhD ^c and Alessandro Padovani, MD, PhD ^a
8	
9	^a Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia,
10	Brescia, Italy
11	
12	^b FERB Onlus, Ospedale S. Isidoro, Trescore Balneario, Bergamo, Italy
13	
14	^c Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of
15	Chieti-Pescara, Chieti, Italy
16	
17	^d Division of Pharmacology, Department of molecular and Translational Medicine, University
18	of Brescia, Brescia, Italy
19	
20	^e Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway and
21	Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience,
22	Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK
23	
24	

1	^f Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology,
2	The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3	
4	^g Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
5	
6	^h Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
7	
8	ⁱ UK Dementia Research Institute at UCL, London, UK
9	
10	^j Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and
11	Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the
12	University of Gothenburg, Sweden
13	
14	^k King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl
15	Clinical Neuroscience Institute, London, UK
16	
17	¹ NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for
18	Dementia at South London & Maudsley NHS Foundation, London, UK
19	
20	*Corresponding author:
21	
22	Andrea Pilotto, MD
23	Neurology Unit
24	Department of Clinical and Experimental Sciences
25	University of Brescia
26	P.zale Spedali Civili, 1 - 25123 Brescia, Italy

1	Ph. +39-030-3995632
2	Fax +39-030-3995027
3	Email: pilottoandreae@gmail.com
4	
5	^{\$} Andrea Pilotto and Alberto Imarisio equally contributed to the present work.
6	
7	Running Title: Plasma NfL predicts cognitive progression in DLB
8	Word Count Manuscript: 2044 words Abstract: 105 words
9	
10	Number of references: Figures: 1 Tables: 2 + 1 supplementary table.
11	Keywords: Dementia with Lewy Bodies; neurofilament light chain; cognitive progression;
12	biomarkers.
13	
14	Authorship
15	Andrea Pilotto: study concept and design, acquisition of data, analysis and interpretation of
16	data, drafting/revising the manuscript for content.
17	Alberto Imarisio: study concept and design, acquisition of data, analysis and interpretation of
18	data, drafting/revising the manuscript for content.
19	Claudia Carrarini: acquisition of data, drafting/revising the manuscript for content.
20	Mirella Russo: acquisition of data, drafting/revising the manuscript for content.
21	Stefano Masciocchi: acquisition of data, drafting/revising the manuscript for content.
22	Stefano Gipponi: acquisition of data, drafting/revising the manuscript for content.
23	Elisabetta Cottini: acquisition of data, drafting/revising the manuscript for content.
24	Dag Aarsland: drafting/revising the manuscript for content.
25	Henrik Zetterberg: study concept and design, acquisition of data, analysis and interpretation
26	of data, drafting/revising the manuscript for content.

 manuscript for content. Abdul Hye: acquisition of data, analysis and interpretation of manuscript for content. Laura Bonanni: acquisition of data, analysis and interpretation manuscript for content. Alessandro Padovani: acquisition of data, analysis and interpretation the manuscript for content. the manuscript for content. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 	tion of data, drafting/revising the
 manuscript for content. Laura Bonanni: acquisition of data, analysis and interpretation manuscript for content. Alessandro Padovani: acquisition of data, analysis and interpretation the manuscript for content. the manuscript for content. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 	
 Laura Bonanni: acquisition of data, analysis and interpretation manuscript for content. Alessandro Padovani: acquisition of data, analysis and interpretation the manuscript for content. the manuscript for content. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 	f data, drafting/revising the
 manuscript for content. Alessandro Padovani: acquisition of data, analysis and interpretente the manuscript for content. the manuscript for content. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 	
 Alessandro Padovani: acquisition of data, analysis and interpretents the manuscript for content. iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	on of data, drafting/revising the
8 the manuscript for content. 9 10 10 11 11 12 12 13 13 14 15 16 16 17 18 19 20 21 21 22 22 23 24 25	
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	pretation of data, drafting/revising
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	
12 13 14 15 16 17 18 19 20 21 22 23 24 25	
13 14 15 16 17 18 19 20 21 22 23 24 25	
14 15 16 17 18 19 20 21 22 23 24 25	
15 16 17 18 19 20 21 22 23 24 25	
16 17 18 19 20 21 22 23 24 25	
17 18 19 20 21 22 23 24 25	
18 19 20 21 22 23 24 25	
19 20 21 22 23 24 25	
20 21 22 23 24 25	
21 22 23 24 25	
22 23 24 25	
23 24 25	
24 25	
25	
26	

6 ABSTRACT

Plasma neurofilament light chain (NfL) is a marker of neuronal damage in different neurological disorders and might predict disease progression in dementia with Lewy bodies (DLB). The study enrolled 45 controls and 44 DLB patients (including 17 prodromal cases) who underwent an extensive assessment at baseline and at 2 years follow-up. At baseline, plasma NfL levels were higher in both probable DLB and prodromal cases compared to controls. Plasma NfL emerged as the best predictor of cognitive decline compared to age, sex and baseline severity variables. The study supports the role of plasma NfL as a useful prognostic biomarker from the early stages of DLB.

- 1
- 2
- 3
- 4
- 5

6 INTRODUCTION

7

8 Dementia with Lewy Bodies (DLB) is a complex neurodegenerative disorder characterized 9 pathologically by misfolding and aggregation of alpha-synuclein, as well as A-beta and tau 10 proteins, and by a combination of cognitive deficits with fluctuations, visual hallucinations, 11 parkinsonism, REM-sleep behavior disorder (RBD) which represent the core clinical 12 symptoms and is often associated with behavioral abnormalities and autonomic symptoms [1-13 4]. The prognosis is poor [5] and the variation in cognitive decline is large [6]. 14 Despite the recent advances in the clinical definition of DLB from prodromal stages, 15 disentangling the heterogeneity of presentation and disease progression of patients is still a 16 great challenge for the research community [3]. 17 Diagnosing and stratifying DLB patients are pivotal for a proper personalization of 18 management strategies and identifying patients with different rate of progression will enable a 19 proper selection of patients in incoming disease-modifying interventions. 20 Neurofilament light chain (NfL), a highly expressed protein in large caliber myelinated axons, 21 has been recently proposed as general marker of neuronal degeneration and damage in 22 different neurological disorders [7,8]. In fact, CSF and plasma NfL levels are significantly 23 altered in Alzheimer's disease (AD) and other neurodegenerative conditions, whereas 24 findings in Parkinson's disease (PD) and early DLB were contradictory [9]. In addition to 25 that, it has been reported that plasma and CSF NfL levels correlated with disease severity and

progression in PD [8,10,11] and Alzheimer's disease [12]. Very few studies have focused on DLB patients and, to the best of our knowledge, no prospective longitudinal studies evaluated plasma NfL as potential early diagnostic and prognostic marker in DLB. Therefore, the aim of the present study was to investigate the relationships between plasma NfL and motor and cognitive symptoms in DLB from the prodromal stage and to evaluate its accuracy as predictor of progression after two-years of follow-up.

7 **METHODS**

8 Patients selection and assessment

9 Consecutive patients with a clinical diagnosis of probable DLB [2] or prodromal DLB [3] 10 were enrolled between October 2016 and March 2018 for the baseline evaluation at the 11 Neurology Unit at the University of Brescia, Italy and the Neurology Unit at the University G. 12 d'Annunzio of Chieti-Pescara, Chieti, Italy. Healthy controls subjects (HC) with normal 13 cognitive and motor functions were recruited among patients' caregivers This study was 14 approved by the local ethics committee (NP 1471, DMA, Brescia) and was in conformity with 15 the Helsinki Declaration; informed consent was obtained from all participants. All patients underwent routine blood analyses, magnetic resonance imaging (MRI) and [¹²³I]FP-CIT 16 17 SPECT imaging supporting the diagnosis [13]; levodopa equivalent daily dose (LEDD) was 18 calculated according to standard conversion [14] and the diagnosis was supported by at least 19 one year of clinical follow-up.

The following exclusion criteria were applied: (1) cognitive deficits or dementia due to other causes than DLB; (2) prominent cortical or subcortical infarcts or brain/iron accumulation at imaging; (3) other neurologic disorders or medical conditions potentially associated with cognitive deficits; (4) bipolar disorder, schizophrenia, history of drug or alcohol abuse or impulse control disorder; (5) recent traumatic events or acute fever/inflammation.

1 At baseline, standardized neurological examination was performed, including the Movement 2 Disorder Society- Unified Parkinson Disease Rating Scale, part III (MDS-UPDRS, part III) 3 [15], a full neuropsychological assessment including the Mini-Mental State Examination 4 (MMSE), the Neuropsychiatric Inventory (NPI) [16] and an evaluation of basic and 5 instrumental activities of daily living [17]. DLB patients without dementia (i.e., independent 6 in activities of daily living) at baseline and two years - follow-up were retrospectively re-7 classified as prodromal DLB according to recently proposed diagnostic criteria [3]. 8 Each DLB patient was stratified according to the cut-off value established as 80th percentile 9 of healthy individuals in the age-specific category [18], into subject with abnormal high (H-10 NfL) or normal NfL levels (N-NfL). All patients included in the analyses underwent a clinical 11 follow-up at 2 years including full neurological examination, motor, cognitive and 12 behavioural assessment.

13

14 **Biochemical analyses**

15 At the time of assessment, approximately 10 mL venous blood was collected in glass tubes containing sodium ethylenediaminetetraacetic acid (EDTA) from each subject. The blood 16 17 samples were centrifuged at 2000 x g at 4 °C for 8 min within 2 h of collection. Plasma 18 supernatant was collected, divided into aliquots, and frozen at -80 °C until further use. Neat 19 plasma NfL concentration was measured using the Simoa HD-1 platform (NF-Light; 20 Quanterix, Billerica, MA) at the Maurice Wohl Clinical Neuroscience Institute, London, UK. 21 Samples were randomized, blinded and measured in duplicate using a batch of reagents from 22 the same lot. The lower limit of quantification was 0.136 pg/mL and the lower limit of 23 quantification (LLOQ) was 0.696 pg/mL when compensated for a 4-fold sample dilution. 24 Outliers with plasma NfL value above more than 5 standard deviations of the mean were 25 excluded from the study analysis (n = 1 probable DLB; n = 1 HC) [19].

1 Statistical analyses.

2	Group differences between HC and total DLB, as well as between probable DLB and
3	prodromal DLB and between N-NfL and H-NfL were assessed with Mann-Whitney U test or
4	Fisher exact test for continuous or dichotomous variables, respectively. Plasma NfL levels
5	between groups were compared with age-adjusted one-way ANOVA. Progression of MMSE,
6	MDS-UPDRS-III and NPI between groups was evaluated with repeated measures ANOVA
7	adjusted for age, sex, disease duration, baseline MMSE and MDS-UPDRS-III (for MMSE
8	and MDS-UPDRS-III progression) and for age, sex, disease duration, baseline MMSE and
9	baseline NPI (for NPI progression).
9 10	baseline NPI (for NPI progression). Plasma NfL levels and established prognostic factors (age, gender, disease duration, MDS-
10	Plasma NfL levels and established prognostic factors (age, gender, disease duration, MDS-
10 11	Plasma NfL levels and established prognostic factors (age, gender, disease duration, MDS- UPDRS III score, MMSE and NPI) were analyzed by a multivariable linear regression in
10 11 12	Plasma NfL levels and established prognostic factors (age, gender, disease duration, MDS- UPDRS III score, MMSE and NPI) were analyzed by a multivariable linear regression in order to evaluate the best predictors of changes within cognitive (MMSE), behavioral (NPI)

16

17 **RESULTS**

18 *Recruitment, clinical and cognitive baseline features*

Forty-four DLB patients (including 27 with dementia and 17 prodromal cases) and forty-five healthy controls were consecutively enrolled. Three patients deceased during the follow-up and 41 patients were thus included in the longitudinal analyses. Between prodromal DLB patients (n = 17), n = 13 were diagnosed as probable MCI-LB, n = 3 as psychiatric-onset prodromal DLB and n = 1 as delirium-onset prodromal DLB. According to the definition, prodromal cases were independent for activities of daily living and exhibited higher total MMSE scores compared to DLB with dementia (25.5 ± 1.3 vs 18.3 ± 3.7; p = 0.001) Table 1.

1 HC were slightly younger than DLB patients $(73.3 \pm 7.6 \text{ vs } 77.5 \pm 5.4 \text{ years respectively}, p =$ 2 0.003) and comparable for sex distribution. In age-adjusted comparisons, NfL levels were 3 higher in DLB total cohort and separately in both probable DLB and prodromal cases 4 compared to HC (Figure 1 and Table 1, HC 25.7 \pm 10.5 pg/ml, DLB with dementia 55.3 \pm 5 20.9 pg/ml, prodromal DLB $46.9 \pm 23.2 \text{ pg/ml}$; total DLB vs HC: p < 0.001; prod-DLB vs 6 HC: p = 0.001; probable DLB vs HC: p < 0.001). 7 In total DLB cohort, plasma NfL correlated with age (r = 0.369; p = 0.014) and exhibited 8 similar distribution in male and female subjects. In HC group there were no significant

9 associations between NfL levels, age and sex. At the time of baseline assessment, no

10 correlation between NfL levels and disease duration or severity of motor, cognitive and

11 neuropsychiatric features was detected in analyses adjusted for age and sex (in the whole

12 group and separately for prodromal and clinical cases). H-NfL patients were older than N-NfL

13 (79.3 \pm 5.3 vs 75.7 \pm 5.0 years, respectively; p = 0.030), whereas there were no significant

between-group differences in disease duration as well as in cognitive, motor and behavioralbaseline features.

16

17 Plasma NfL as predictor of progression

18 At follow up, the total group of DLB patients exhibited a mean decrease of 3.8 ± 3.1 points at 19 MMSE score, a mean increase of 1.6 ± 1.5 points in total NPI and 2.8 ± 6.8 points in MDS-20 UPDRS-III score. In the model without NfL (model 1, supplementary Table 1), no predictors of changes in MMSE were identified ($R^2 = 0.160$) while the inclusion of NfL (model 2) 21 increased the prediction of the linear model ($R^2 = 0.356$) and age (p = 0.047) and NfL (p =22 23 0.034) were the only significant predictors of changes in MMSE (Table 2). No predictors of 24 NPI progression were detected in linear regression model, whereas male gender was the only 25 predictor of Δ MDS-UPDRS-III in the model with ($\beta = 0.387$, p = 0.023) and without ($\beta =$ 0.373, p = 0.026) the inclusion of NfL (Supplementary table 1). At follow-up, 10 out of 17 26

prodromal cases converted to dementia with Lewy bodies; converters did not differ for
 demographic or clinical baseline variables and exhibited slightly higher but not significant
 NfL levels compared with non-converters (51.4 ± 22.9 vs 40.5 ± 23.9; p = 0.37)
 (Supplementary Table 2).

5

7

6 **DISCUSSION**

8 This is the first longitudinal study addressing plasma NfL as an early diagnostic and 9 prognostic marker in DLB patients. We found higher NfL levels in DLB patients compared 10 with controls from the prodromal stages and we demonstrated for the first time that baseline 11 NfL levels predicted cognitive decline over a follow-up of 2 years.

12

13 The study included consecutive patients with a clinical diagnosis of probable DLB and a 14 subset of prodromal cases who underwent an extensive motor, cognitive and behavioral 15 assessment. We demonstrated that clinical DLB cases exhibited increased plasma NfL levels 16 compared with controls, in line with several cross-sectional studies focused on 17 neurodegenerative disorders [7,20]. Furthermore, the findings showed that cases who 18 retrospectively fulfilled the newly proposed prodromal DLB criteria [3] exhibited already 19 increased plasma NfL levels compared with controls [18]. These important results strongly 20 support the usefulness of plasma NfL as diagnostic marker of DLB already in the prodromal 21 stages, in line with the work of Delaby and colleagues [21] based on CSF data on DLB with 22 and without dementia. 23 In addition, our study aimed to define whether plasma NfL levels might be of prognostic

value, a still unsolved issue with great relevance for the upcoming disease-modifying trials.

25 Indeed, the identification of consistent disease progression markers is still an open challenge

26 for DLB. Recently, a growing number of studies identified EEG, imaging or CSF

abnormalities to be associated with faster progression already in early DLB stages [22–24].
 However, these techniques definitively need further validations to be applied in clinical
 practice.

4 In the present study, we identified higher blood NfL levels as a significant predictor of faster 5 cognitive progression in DLB patients at 2 year follow-up. These results were strengthened by 6 a linear regression model taking into account age, sex and the baseline clinical data for both 7 clinical and prodromal DLB patients. These findings are at variance with two earlier studies 8 performed on CSF, that failed to demonstrate a relationship between NfL levels and annual 9 MMSE decline [25][26] in smaller group of DLB patients. Of note, the prognostic value of 10 NfL was specifically demonstrated for cognitive changes, whereas was not confirmed for 11 behavioral and motor progression in the cohort. This fit with data coming from studies on 12 Alzheimer's disease [12] but also with Parkinson's disease in which higher NfL levels have 13 been more consistently associated with cognitive decline [10].

14 Several limitations should be acknowledged. First, a 2-year follow-up period is a short 15 interval to consider these findings as definitive, and further validations in longer and larger 16 longitudinal multicentre studies are needed in order to evaluate the long-term value of NfL in 17 predicting progression on disability milestones. Second, the small sample size required the 18 use of non-parametric statistical analysis and limited the number of covariates in linear 19 regression model, and since this was an exploratory study we did not adjust for multiple 20 statistical comparisons. Third, the study evaluated clinical outcomes and the findings need to 21 be replicated against imaging, CSF, neurophysiological markers. Furthermore, the patients 22 were not stratified according to genetics (i.e. APOE or GBA) and concomitant AD pathology, 23 known to be associated with worse progression of DLB [27, 28]. Diagnosis was clinical 24 associated with DAT imaging but without autopsy confirmation, and the prodromal criteria 25 were applied retrospectively. However, the longitudinal design and standardized 26 comprehensive clinical assessments and use of the most recent consensus diagnostic criteria

1	ensures a high diagnostic accuracy. Limitations notwithstanding, this is the first study
2	demonstrating the diagnostic and prognostic value of plasma NfL in DLB already from
3	prodromal stages.
4	
5	
6	ACKNOWLEDGMENTS
7	The authors thanks all the participants for their participation.
8	
9	Study funding: The recruitment of patients was partially supported by BIOMANE Project
10	from the Health and Wealth research grants 2016 of the University of Brescia [grant number
11	NP 1471, DMA].
12	
13	Relevant conflicts of interest/financial disclosures (for the past two years): all the authors
14	report no disclosures related to this manuscript. Other disclosures are reported below.
15	
16	Andrea Pilotto served in the advisory board of Z-cube (technology division of Zambon
17	pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Nutricia and
18	Chiesi pharmaceuticals. He received research support from Vitaflo Germany and Zambon
19	Italy.
20	Alberto Imarisio has no financial conflicts to disclose.
21	Claudia Carrarini has no financial conflicts to disclose.
22	Mirella Russo has no financial conflicts to disclose.
23	Stefano Masciocchi has no financial conflicts to disclose.
24	Stefano Gipponi has no financial conflicts to disclose.
25	Elisabetta Cottini has no financial conflicts to disclose.

1	Dag Aarsland has received research support and/or honoraria from Astra-Zeneca, H.			
2	Lundbeck, Novartis Pharmaceuticals, Evonik, and GE Health, and served as paid consultant			
3	for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly and Biogen.			
4	Henrik Zetterberg has served at scientific advisory boards for Denali, Roche Diagnostics,			
5	Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectur			
6	in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain			
7	Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubate			
8	Prog	gram (outside submitted work).		
9	Nicholas Ashton has no financial conflicts to disclose.			
10	Abdul Hye has no financial conflicts to disclose.			
11	Lau	a Bonanni received unrelated national grants from the Italian Ministry of Health, from		
12	Euro	opean Commission (PD MIND project, IMI call) and from Mentis cura, Oslo srl; fees		
13	from	G.E. Healthcare for teaching courses. Served as reviewer for NIHhas no financial		
14	conflicts to disclose.			
15	Alessandro Padovani is consultant and served on the scientific advisory board of GE			
16	Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from			
17	Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi			
18	Phar	maceuticals. He is founded by Grant of Ministry of University (MURST).		
19				
20				
21				
22 23	REFERENCES			
24 25	[1]	Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet		
26		386 , 1683–1697.		
27	[2]	McKeith IG, Boeve BF, DIckson DW, Halliday G, Taylor JP, Weintraub D, Aarsland		

1		D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N,
2		Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O,
3		Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts
4		SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee
5		VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P,
6		Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S,
7		Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A,
8		Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K
9		(2017) Diagnosis and management of dementia with Lewy bodies. Neurology 89, 88-
10		100.
11	[3]	McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K,
12		Muscio C, O'Brien JT, Postuma RB, Aarsland D, Ballard C, Bonanni L, Donaghy P,
13		Emre M, Galvin JE, Galasko D, Goldman JG, Gomperts SN, Honig LS, Ikeda M,
14		Leverenz JB, Lewis SJG, Marder KS, Masellis M, Salmon DP, Taylor JP, Tsuang DW,
15		Walker Z, Tiraboschi P, prodromal DLB Diagnostic Study Group (2020) Research
16		criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94, 743-
17		755.
18	[4]	Pilotto A, Romagnolo A, Tuazon JA, Vizcarra JA, Marsili L, Zibetti M, Rosso M,
19		Rodriguez-Porcel F, Borroni B, Rizzetti MC, Rossi C, Vizcarra-Escobar D, Molano JR,
20		Lopiano L, Ceravolo R, Masellis M, Espay AJ, Padovani A, Merola A (2019)
21		Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical
22		outcomes in α-synucleinopathies. J Neurol Neurosurg Psychiatry 90, 1257-1263.
23	[5]	Mueller C, Ballard C, Corbett A, Aarsland D (2017) The prognosis of dementia with
24		Lewy bodies. Lancet Neurol 16, 390–398.
25	[6]	Giil LM, Aarsland D (2020) Greater Variability in Cognitive Decline in Lewy Body
26		Dementia Compared to Alzheimer's Disease. J Alzheimer's Dis 73, 1321–1330.

1	[7]	Ashton N, Janelidze S, Al Khleifat A, Leuzy A, Van Der Ende E, Karikari T, Benedet
2		A, Pascoal T, Lleó A, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J,
3		Novakova L, Axelsson M, Velayudhan L, Rabinovici G, Miller B, Pariante C, Resnick
4		S, Schöll M, Fernandez-Eulate G (2021) Diagnostic value of plasma neurolament light:
5		A multicentre validation study. Unpubl data.
6	[8]	Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S,
7		Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni
8		T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A,
9		Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D (2020) Validation of Serum
10		Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Mov
11		Disord 35, 1999–2008.
12	[9]	Bridel C, Van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-
13		Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M,
14		Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L,
15		Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK,
16		Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi
17		M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J,
18		Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson
19		T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson
20		O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg
21		FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R,
22		Tortorella C, Trentini A, Troiano M, Turner MR, Van Swieten JC, Vågberg M,
23		Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ (2019)
24		Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A
25		Systematic Review and Meta-analysis. JAMA Neurol 76, 1035–1048.
26	[10]	Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ (2019) Blood NfL: A

biomarker for disease severity and progression in Parkinson disease. *Neurology* 93,
 e1104–e1111.

- 3 Bäckström D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, [11] 4 Forsgren L, Lenfeldt N (2020) NfL as a biomarker for neurodegeneration and survival 5 in Parkinson disease. Neurology 95, e827-e838. 6 Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, [12] 7 Suárez-Calvet M, Blennow K, Zetterberg H, Schöll M (2021) Longitudinal 8 Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain with 9 Neurodegeneration in Alzheimer Disease. JAMA Neurol. 78:396-406 10 Pilotto A, Cola FS di, Premi E, Grasso R, Turrone R, Gipponi S, Scalvini A, Cottini E, [13] 11 Paghera B, Garibotto V, Rizzetti MC, Bonanni L, Borroni B, Morbelli S, Nobili F, 12 Guerra UP, Perani D, Padovani A (2019) Extrastriatal dopaminergic and serotonergic 13 pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT 14 SPECT study. Eur J Nucl Med Mol Imaging. 15 Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review [14] of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25, 2649-16 17 53. 18 [15] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe 19 W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, 20 Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, 21 Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society UPDRS 22 Revision Task Force (2008) Movement Disorder Society-sponsored revision of the 23 Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and 24 clinimetric testing results. Mov Disord 23, 2129-70. 25 Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in [16]
- dementia patients. *Neurology* **48**,.

1	[17]	Pilotto A, Turrone R, Liepelt-Scarfone I, Bianchi M, Poli L, Borroni B, Alberici A,
2		Premi E, Formenti A, Bigni B, Cosseddu M, Cottini E, Berg D, Padovani A (2016)
3		Vascular risk factors and cognition in Parkinson's disease. J Alzheimer's Dis 51,.
4	[18]	Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C,
5		Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J (2017) Serum
6		Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann
7		<i>Neurol</i> 81 , 857–870.
8	[19]	Hodge VJ, Hodge VJ, Austin J (2004) A survey of outlier detection methodologies.
9		Artif Intell Rev 22, 2004.
10	[20]	Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M,
11		Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel
12		M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament Light Chain in
13		Blood and CSF as Marker of Disease Progression in Mouse Models and in
14		Neurodegenerative Diseases. Neuron 91, 56–66.
15	[21]	Delaby C, Alcolea D, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta
16		I, Altuna M, Estellés T, Santos-Santos M, Turon-Sans J, Muñoz L, Ribosa-Nogué R,
17		Sala-Matavera I, Sánchez-Saudinos B, Subirana A, Videla L, Benejam B, Sirisi S,
18		Lehmann S, Belbin O, Clarimon J, Blesa R, Pagonabarraga J, Rojas-Garcia R, Fortea J,
19		Lleó A (2020) Differential levels of Neurofilament Light protein in cerebrospinal fluid
20		in patients with a wide range of neurodegenerative disorders. Sci Rep 10, 1–8.
21	[22]	Bonanni L, Perfetti B, Bifolchetti S, Taylor J-P, Franciotti R, Parnetti L, Thomas A,
22		Onofrj M (2015) Quantitative electroencephalogram utility in predicting conversion of
23		mild cognitive impairment to dementia with Lewy bodies. Neurobiol Aging 36, 434-
24		45.
25	[23]	van der Zande JJ, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ,

26 Lemstra AW (2020) Diagnostic and prognostic value of EEG in prodromal dementia

with Lewy bodies. Neurology 95, e662–e670.

2	[24]	Nedelska Z, Schwarz CG, Lesnick TG, Boeve BF, Przybelski SA, Lowe VJ, Kremers
3		WK, Gunter JL, Senjem ML, Graff-Radford J, Ferman TJ, Fields JA, Knopman DS,
4		Petersen RC, Jack CR, Kantarci K (2019) Association of Longitudinal β-Amyloid
5		Accumulation Determined by Positron Emission Tomography With Clinical and
6		Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Netw open 2,
7		e1916439.
8	[25]	Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund
9		K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L,
10		Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VMY, Trojanowski
11		JQ, Blennow K (2019) Association of Cerebrospinal Fluid Neurofilament Light Protein
12		Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and
13		Movement Disorders. JAMA Neurol 76, 318–325.
14	[26]	Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo
15		P, Ladogana A, Parchi P (2018) The CSF neurofilament light signature in rapidly
16		progressive neurodegenerative dementias. Alzheimer's Res Ther 10: 3
17	[27]	Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A, Preische O,
18		Stransky E, Deuschle C, Hauser AK, Schulte C, Lachmann I, Waniek K, Gasser T,
19		Berg D, Maetzler W, Brockmann K (2019) Dementia with lewy bodies: GBA1
20		mutations are associated with cerebrospinal fluid alpha-synuclein profile. Mov Disord.
21		2019 Jul;34(7):1069-1073. doi: 10.1002/mds.27731.
22	[28]	Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG,
23		Zetterberg H, Mollenhauer B, Boada M, Arsland D (2016) Alzheimer's disease
24		cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
25		Movement Disorders, 31(8), 1203–1208. https://doi.org/10.1002/mds.26668

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
10	
19	Table 1. Clinical and demographic characteristics of prodromal DLB and probable DLB
20	patients at baseline and after 2-years follow-up.
21	

	НС	Total	Prodromal	Probable	p - value ^{\$}
	(n = 45)	(n = 44)	DLB	DLB	
			(n = 17)	(n = 27)	
Age, years	73.3 ± 7.6	77.5 ± 5.4	77.2 ± 4.8	77.7 ± 5.8	0.181 ^a
Sex M, n (%)	20 (44.4)	18 (40.9)	9 (52.9)	9 (33.3)	0.225 ^b
Disease duration, years	-	3.8 ± 3.0	3.4 ± 3.0	4.1 ± 3.0	0.256 ^a
NfL, pg/ml	25.7 ± 10.5	52.0 ± 22.0	46.9 ± 23.2	55.3 ± 20.9	0.181ª
Independence in functional	45 (100)	17 (38.6)	17 (100)	0 (0)	< 0.001 ^b
activities, n (%)					
MMSE, total score	29.1 ± 0.8	21.2 ± 4.6	25.5 ± 1.3	18.3 ± 3.7	< 0.001 ^a
NPI total score	-	20.5 ± 16.1	15.2 ± 10.1	23.6 ± 18.3	0.191 ^a
MDS-UPDRS-III, total	-	24.8 ± 13.6	23.1 ± 11.6	26.0 ± 14.8	0.655ª
LEDD, mg/day	-	254.2 ±	240.0 ± 213.1	262.7 ± 222.9	0.818 ^a
Follow-up at two years					
AMMSE	-	-3.8 ± 3.1	-3.9 ± 3.1	- 3.8 ± 3.1	0.856 ^c
ΔΝΡΙ	-	1.6 ± 1.5	1.2 ± 1.6	4.8 ± 3.5	0.151°
AMDS-UPDRS-III	-	2.8 ± 6.8	2.4 ± 7.2	3.2 ± 6.8	0.755°

3 Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease

4 Rating Scale, part III; Δ MDS-UPDRS-III = (MDS-UPDRS-III_{2 years} - MDS-UPDRS-III_{baseline});

5 MMSE, Minimental State Examination; $\Delta MMSE = (MMSE_{2years} - MMSE_{baseline}); NfL,$

6 neurofilament light chain; NPI = neuropsychiatric inventory; $\Delta NPI = (NPI_{2years} - NPI_{baseline})$.

7 ^{\$}Comparison between prodromal and probable DLB subgroups have been performed by ^a

8 Mann-Whitney U test or ^b Fisher exact test or ^c repeated measures model adjusted for the


1	effect of age, sex, disease duration, baseline MDS-UPDRS-III, baseline MMSE (for Δ MDS-
2	UPDRS-III and Δ MMSE) and for age, sex, disease duration, baseline MDS-UPDRS-III,
3	baseline MMSE and baseline NPI (for Δ NPI).
4	

Table 2. Multivariable linear regression model for cognitive progression in total DLB cohort
defined by changes in MMSE score including demographic, clinical baseline variables and
plasma NfL levels.

Independent variables	В	Standard error	Beta	t	p-value
Constant	-18,484	8,163		-2,264	0,030
age	0,204	0,099	0,348	2,065	0,047
Gender	1,444	0,947	0,236	1,524	0,137
Disease duration	-0,284	0,171	-0,294	-1,657	0,107
MMSEbaseline	-0,026	0,109	-0,038	-0,239	0,813
MDS-UPDRS-IIIbaseline	0,043	0,037	0,193	1,152	0,258
NfL	-0,050	0,022	-0,361	-2,218	0,034

Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease
Rating Scale, part III; MMSE, Minimental State Examination. NfL, neurofilament light chain.
Figure 1. Box and whiskers plot showing plasma NfL levels in HC, prod-DLB and DLB

19 patients.



Data are shown as medians with 25°-75° percentiles (boxes), min-max values (whiskers) and
individual values (dots). DLB = probable Dementia with Lewy Bodies; HC = healthy
controls; NfL = neurofilament light chain; prod-DLB = prodromal Dementia with Lewy
Bodies; * p = 0.001; ** p < 0.001.

- 9
- 10
- 11 12

13 Supplementary Table 1

Multivariable linear regression for factors associated with cognitive, motor and behavioral
progression.

17 Model a) included demographic and clinical variables but no NfL at baseline for cognitive

18 progression in total DLB cohort defined by changes within MMSE score. Models b) and c)

19 showed the predicting models of motor progression defined by MDS-UPDRS-III (b) and

20 behavioral abnormalities defined by NPI changes (c)

a) Model for MMSE changes without NfL

Independent variables	В	Standard error	Beta	t	p-value
Constant	-16,094	8,558		-1,881	0,069
age	0,143	0,100	0,244	1,428	0,163
Gender	1,191	0,994	0,195	1,198	0,239
Disease duration	-0,290	0,181	-0,300	-1,602	0,119
MMSEbaseline	-0,010	0,115	-0,015	-0,087	0,931
MDS-UPDRS-IIIIbaseline	0,035	0,039	0,159	0,902	0,374
b) Model for MDS-UPDR	S-III change	es with NfL			
Constant	35,693	19,178		1,861	0,072
Age	-0,301	0,232	-0,229	-1,297	0,204
Gender	-5,302	2,225	-0,387	-2,383	0,023
Disease duration	-0,077	0,403	-0,036	-0,192	0,849
MMSEbaseline	-0,151	0,256	-0,099	-0,589	0,560
MDS-UPDRS-IIIIbaseline	0,007	0,088	0,014	0,083	0,935
NfL	0,039	0,053	0,126	0,736	0,467
c) Model for NPI changes with NfL					
Constant	-4,968	36,745		-0,135	0,893
age	0,370	0,440	0,162	0,841	0,408
Gender	-5,784	4,065	-0,239	-1,423	0,166
Disease duration	-0,507	0,774	-0,134	-0,655	0,518
MMSEbaseline	0,157	0,488	0,059	0,322	0,750
MDS-UPDRS-IIIIbaseline	-0,119	0,155	-0,139	-0,766	0,450
NPI total scorebaseline	-0,158	0,146	-0,210	-1,081	0,289

NfL

Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease
 Rating Scale, part III; MMSE, Minimental State Examination; NfL, neurofilament light chain;
 NPI, neuropsychiatric inventory.

- 5
- 6

Supplementary Table 2. Clinical and demographic characteristics of prodromal DLB
 converters and non-converters to dementia at baseline and after 2-years follow-up.

	Converters	Non-	p - value
	(n = 10)	converters	
		(n = 7)	
Age, years	77.8 ± 4.6	76.3 ± 5.3	0.303 ^a
Sex M, n (%)	6 (60.0)	3 (43)	0.637 ^b
Disease duration, years	4.3 ± 3.6	2.1 ± 4.3	0.083 ^a
NfL, pg/ml	51.4 ± 22.9	40.5 ± 23.9	0.370 ^a
NfL-H, %	5 (50.0)	2 (28.6)	0.354 ^b
MMSE, total score	25.3 ± 1.3	25.7 ± 1.3	0.454 ^a
NPI total score	14.1 ± 9.6	16.8 ± 11.4	0.826 ^a
MDS-UPDRS-III, total score	22.9 ± 10.7	23.3 ± 13.7	0.961ª
LEDD, mg/day	355.6 ± 181.0	100.0 ± 141.4	0.010 ^a
Follow-up at two years		1	

ΔΜΜSE	-6.2 ± 1.8	-0.7 ± 1.0	< 0.001°
ΔΝΡΙ	12.0 ± 21.9	1.2 ± 1.2	0.498 ^c
AMDS-UPDRS-III	5.9 ± 7.0	1.6±5.4	0.078 ^c

3	Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson's Disease
4	Rating Scale, part III; Δ MDS-UPDRS-III = (MDS-UPDRS-III _{2 years} - MDS-UPDRS-III _{baseline});
5	MMSE, Minimental State Examination; $\Delta MMSE = (MMSE_{2years} - MMSE_{baseline})$; NfL,
6	neurofilament light chain; NPI = neuropsychiatric inventory; $\Delta NPI = (NPI_{2years} - NPI_{baseline})$.
7	^{\$} Comparison between Converters and Non-converters subgroups have been performed by ^a
8	Mann-Whitney U test or ^b Fisher exact test or ^c repeated measures model adjusted for the
9	effect of age, sex, disease duration, baseline MDS-UPDRS-III, baseline MMSE (for Δ MDS-
10	UPDRS-III and Δ MMSE) and for age, sex, disease duration, baseline MDS-UPDRS-III,
11	baseline MMSE and baseline NPI (for Δ NPI).